Trial · NCT07120971
Metformin for Premature Infants With Bronchopulmonary Dysplasia
NCT07120971, Early phase 1, Recruiting, Medical College of Wisconsin
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Metformin for Premature Infants With Bronchopulmonary Dysplasia. Trials, record NCT07120971. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07120971
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Metformin for Premature Infants With Bronchopulmonary Dysplasia
- NCT number
- NCT07120971
- Status
- Recruiting
- Phases
- Early phase 1
- Enrollment
- 40 participants, estimated
- Lead sponsor
- Medical College of Wisconsin
- Conditions
- Bronchopulmonary Dysplasia (BPD)
- Interventions
Metformin (open-label), Metformin (open-label), Metformin (open-label), Metformin (open-label), Metformin (open-label), Metformin (open-label), Metformin (open-label), Metformin (open-label), Metformin (open-label)
- First posted
- 2025-08-13
- Last updated
- 2026-01-26
Source ClinicalTrials.gov
Registered outcomes14
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Number of participants who tolerate metformin | 14 days after administration of the first dose of metformin | Number of subjects who receive enteral doses of metformin and complete the study days without an adverse event while continuing enteral feedings |
| Primary | Number of participants with treatment-related adverse events | 14 days after administration of the first dose of metformin | Number of participants who develop hypoglycemia defined as blood glucose value \<50 |
| Primary | Number of participants with treatment-related metabolic acidosis | 14 days after administration of the first dose of metformin | Number of subjects who develop lactic acid levels \> 5mmol/L |
| Primary | Number of subjects with treatment-related feeding problems | 14 days after administration of the first dose of metformin | Number of subjects who require a decrease in enteral feeding volume by \>50% from baseline |
| Primary | Number of subjects who require dose adjustments of metformin | 14 days after administration of the first dose of metformin | Number of subjects who need decreases in dose or discontinuation of metformin due to hepatic or renal dysfunction |
| Primary | Number of subjects with respiratory deterioration | 14 days after administration of the first dose of metformin | Number of subjects who develop pneumonia and increases in oxygen concentration and ventilator support during the study |
| Primary | Number of subjects who complete pharmacokinetic evaluation of metformin | 14 days after administration of the first dose of metformin | Number of subjects who have at least one metformin concentration in blood measured at 1, 4 and 12 hours after an enteric dose |
| Primary | Pharmacokinetic analysis of metformin | 14 days after administration of the first dose of metformin | Area under the curve of Plasma Concentration Versus Time (AUC) of metformin over a time frame of 1, 4 and 12 hours after an enteric dose of metformin. |
| Primary | Number of subjects who complete the treatment protocol | 14 days after administration of the first dose of metformin | Number of subjects who complete the study doses of enteric metformin |
| Secondary | Incidence of bronchopulmonary dysplasia | 14 days after administration of the first dose of metformin | Number of subjects who are diagnosed with bronchopulmonary dysplasia |
1 to 10 of 14Source ClinicalTrials.gov
See all 14 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers22
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07120971
GET https://conductscience.org/api/trials/v1/NCT07120971/papers?page=2